# Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™
Canonical URL: https://biopharmsignal.com/news/ORTX/orchard-therapeutics-announces-multiple-data-presentations-and-receives-2025-new-treatment-award-at-the-21st-annual-worldsymposiumtm
Ticker: ORTX
Company: Orchard Therapeutics
Source: Orchard Therapeutics
Published: 2025-02-03 13:45 EST
Original Source URL: https://ir.orchard-tx.com
## Summary

Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety of tissues and organs, including the CNS TOKYO, LONDON and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, today

## Article Body
Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety of tissues and organs, including the CNS TOKYO, LONDON and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, today
## Recent Company News
- 2025-12-16 17:15 EST — [Orchard Therapeutics Celebrates Addition of Metachromatic Leukodystrophy to the U.S. Recommended Uniform Screening Panel](https://biopharmsignal.com/news/ORTX/orchard-therapeutics-celebrates-addition-of-metachromatic-leukodystrophy-to-the-u-s-recommended-uniform-screening-panel) — Source: Orchard Therapeutics
- 2025-10-28 06:00 EST — [Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan](https://biopharmsignal.com/news/ORTX/kyowa-kirin-and-orchard-therapeutics-announce-otl-200-granted-orphan-regenerative-medicine-product-designation-for-early-onset-mld-in-japan) — Source: Orchard Therapeutics
- 2025-07-07 11:00 EST — [Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome](https://biopharmsignal.com/news/ORTX/orchard-therapeutics-announces-last-patient-treated-in-registrational-trial-of-otl-203-for-mps-i-hurler-syndrome) — Source: Orchard Therapeutics
- 2025-05-13 11:01 EST — [Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025](https://biopharmsignal.com/news/ORTX/orchard-therapeutics-announces-new-england-journal-of-medicine-publication-of-long-term-clinical-outcomes-from-its-hsc-gene-therapy-for-mld-and-multiple-presentations-at-asgct-2025) — Source: Orchard Therapeutics
- 2025-02-12 12:01 EST — [Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD](https://biopharmsignal.com/news/ORTX/orchard-therapeutics-appoints-robin-kenselaar-to-chief-commercial-officer-and-announces-multiple-business-updates-pertaining-to-its-approved-hsc-gene-therapy-for-mld) — Source: Orchard Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)